

Elazar Rabbani et al.

Serial No.: 08/978,633

Filed: November 25, 1997

Page 3 [Amendment Under 37 C.F.R. §1.115 (In Response
to the February 16, 1999 Office Action - August 16, 1999)]

Page 151, line 8, change the first word in this line from "complimentary"
to -- complementary -- .

Page 159, line 11, delete the last word in this line "structures" which is
duplicative of the previous word.

Page 180, line 8, after "assay of the" and before "of the U1" change
"affect" to -- effect -- .

Page 181, line 4, after "CD8-coated" and before "Flasks" change
"(CELLector™" to --(CELLector™ -- .

In The Claims:

~~Cancel~~ claims 2-24.

Amend claims 252, 258, 273, 274, 275, 278, 289, 290, 292, 293 and 296 as
follows:

SUB
E
22
252. (Amended) The composition of claim 247, wherein said nucleic acid
component is selected from the group consisting of a nucleic acid, a nucleic acid
construct, a nucleic acid conjugate, a virus, a viral fragment, a viroid, a phage, a
plasmid, a plasmid vector, a bacterium, [and] a bacterial fragment, [or] and a
combination of the foregoing.

B³
258. (Amended) The composition of claim 257, wherein said ligand binding
receptor is selected from the group consisting of a polynucleotide sequence to be
recognized by its complementary sequence, an antigen to be recognized by its
corresponding monoclonal or polyclonal antibody, an antibody to be recognized by
its corresponding antigen, a lectin to be recognized by its corresponding sugar, a
hormone to be recognized by its receptor, a receptor to be recognized by its
hormone, an inhibitor to be recognized by its enzyme, an enzyme to be recognized
by its inhibitor, a cofactor to be recognized by its cofactor enzyme binding site, a
cofactor enzyme binding site to be recognized by its cofactor, a binding ligand to be
recognized by its substrate, [or] and a combination of the foregoing.

SUP
3
E

273. (Amended) The composition of claim 267, wherein said nucleic acid component is selected from the group consisting of a nucleic acid, a nucleic acid construct, a nucleic acid conjugate, a virus, a viral fragment, a viroid, a phage, a plasmid, a plasmid vector, a bacterium, [and] a bacterial fragment, [or] and a combination of the foregoing.

B⁴

274. (Amended) The composition of claim 267, wherein said domain is selected from the group consisting of covalent bonding, [and] noncovalent binding, [or] and a combination thereof.

275. (Amended) The composition of claim 274, wherein said noncovalent binding is selected from the group consisting of ionic interactions, [and] hydrophobic interactions, [or] and a combination thereof.

B⁵

278. (Amended) The composition of claim 277, wherein said ligand binding receptor is selected from the group consisting of a polynucleotide sequence to be recognized by its complementary sequence, an antigen to be recognized by its corresponding monoclonal or polyclonal antibody, an antibody to be recognized by its corresponding antigen, a lectin to be recognized by its corresponding sugar, a hormone to be recognized by its receptor, a receptor to be recognized by its hormone, an inhibitor to be recognized by its enzyme, an enzyme to be recognized by its inhibitor, a cofactor to be recognized by its cofactor enzyme binding site, a cofactor enzyme binding site to be recognized by its cofactor, a binding ligand to be recognized by its substrate, [or] and a combination of the foregoing.

B⁴

289. (Amended) The composition of claim 286, wherein said binder is selected from the group consisting of a polymer, a matrix, a support, [or] and a combination of any of the foregoing.

RE
SUP
E

290. (Amended) The composition of claim 286, wherein said nucleic acid component is selected from the group consisting of a nucleic acid, a nucleic acid construct, a nucleic acid conjugate, a virus, a viral fragment, a viroid, a phage, a plasmid, a plasmid vector, a bacterium, [and] a bacterial fragment, [or] and a combination of the foregoing.

292. (Amended) The composition of claim 285, wherein said domain is selected from the group consisting of covalent bonding, [and] noncovalent binding, [or] and a combination thereof.

B⁷

293. (Amended) The composition of claim 292, wherein said noncovalent binding is selected from the group consisting of ionic interactions, [and] hydrophobic interactions, [or] and a combination thereof.

B⁸

296. (Amended) The composition of claim 295, wherein said ligand binding receptor is selected from the group consisting of a polynucleotide sequence to be recognized by its complementary sequence, an antigen to be recognized by its corresponding monoclonal or polyclonal antibody, an antibody to be recognized by its corresponding antigen, a lectin to be recognized by its corresponding sugar, a hormone to be recognized by its receptor, a receptor to be recognized by its hormone, an inhibitor to be recognized by its enzyme, an enzyme to be recognized by its inhibitor, a cofactor to be recognized by its cofactor enzyme binding site, a cofactor enzyme binding site to be recognized by its cofactor, a binding ligand to be recognized by its substrate, [or] and a combination of the foregoing.

* * * * *